Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 21

1.

Impact of salmeterol/fluticasone propionate versus salmeterol on exacerbations in severe chronic obstructive pulmonary disease.

Kardos P, Wencker M, Glaab T, Vogelmeier C.

Am J Respir Crit Care Med. 2007 Jan 15;175(2):144-9. Epub 2006 Oct 19.

PMID:
17053207
2.
3.

The role of fluticasone propionate/salmeterol combination therapy in preventing exacerbations of COPD.

Yawn BP, Raphiou I, Hurley JS, Dalal AA.

Int J Chron Obstruct Pulmon Dis. 2010 Jun 3;5:165-78. Review.

4.

Tiotropium bromide. A review of its use as maintenance therapy in patients with COPD.

Keam SJ, Keating GM.

Treat Respir Med. 2004;3(4):247-68. Review.

PMID:
15350163
5.

Inhaled salmeterol/fluticasone propionate combination in chronic obstructive pulmonary disease.

Lyseng-Williamson KA, Keating GM.

Am J Respir Med. 2002;1(4):273-82; discussion 283-4. Review.

PMID:
14720047
6.
7.

Fluticasone propionate/salmeterol for the treatment of chronic-obstructive pulmonary disease.

Dransfield MT, Bailey WC.

Expert Opin Pharmacother. 2004 Aug;5(8):1815-26. Review.

PMID:
15264996
8.

Seretide: a pharmacoeconomic analysis.

Fritscher L, Chapman KR.

J Med Econ. 2008;11(3):555-70. doi: 10.3111/13696990802320908. Review.

PMID:
19450105
9.

Salmeterol/fluticasone combination in the treatment of COPD.

Chung KF.

Int J Chron Obstruct Pulmon Dis. 2006;1(3):235-42. Review.

11.

Budesonide/formoterol vs. salmeterol/fluticasone in COPD: a systematic review and adjusted indirect comparison of pneumonia in randomised controlled trials.

Halpin DM, Gray J, Edwards SJ, Morais J, Singh D.

Int J Clin Pract. 2011 Jul;65(7):764-74. doi: 10.1111/j.1742-1241.2011.02685.x. Review.

PMID:
21676119
12.

Evaluation of salmeterol xinafoate plus fluticasone propionate for the treatment of chronic obstructive pulmonary disease.

Restrepo RD, Tate A, Coquat J.

Expert Opin Pharmacother. 2013 Oct;14(14):1993-2002. doi: 10.1517/14656566.2013.823949. Epub 2013 Jul 31. Review.

PMID:
23898819
13.

Chronic obstructive pulmonary disease megatrials: taking the results into office practice.

Stoloff SW.

Am J Med Sci. 2011 Aug;342(2):160-7. doi: 10.1097/MAJ.0b013e31820879ae. Review.

PMID:
21512392
14.

[Prevention of chronic obstructive pulmonary disease exacerbations].

Dusser D.

Presse Med. 2008 Nov;37(11):1604-8. doi: 10.1016/j.lpm.2008.08.003. Epub 2008 Sep 30. Review. French.

PMID:
18829252
15.

Early chronic obstructive pulmonary disease: definition, assessment, and prevention.

Rennard SI, Drummond MB.

Lancet. 2015 May 2;385(9979):1778-88. doi: 10.1016/S0140-6736(15)60647-X. Review.

16.

Number needed to treat in COPD: exacerbations versus pneumonias.

Suissa S.

Thorax. 2013 Jun;68(6):540-3. doi: 10.1136/thoraxjnl-2012-202709. Epub 2012 Nov 2. Review.

PMID:
23125170
17.

Economic evaluations of fluticasone-propionate/salmeterol combination therapy for chronic obstructive pulmonary disease: a review of published studies.

Roberts MH, Borrego ME, Kharat AA, Marshik PL, Mapel DW.

Expert Rev Pharmacoecon Outcomes Res. 2016;16(2):167-92. doi: 10.1586/14737167.2016.1148602. Epub 2016 Feb 22. Review.

PMID:
26839089
18.

Fixed combination therapies in COPD--effect on quality of life.

Groneberg-Kloft B, Fischer A, Welte T.

Int J Chron Obstruct Pulmon Dis. 2007;2(4):551-7. Review.

19.

Approaches to improving health status in chronic obstructive pulmonary disease: one or several?

Wouters EF.

Proc Am Thorac Soc. 2006 May;3(3):262-9. Review.

PMID:
16636096
20.

[Compliance and persistence with medication in chronic obstructive pulmonary disease].

Agh T, Mészáros A.

Orv Hetil. 2009 Aug 9;150(32):1497-502. doi: 10.1556/OH.2009.28691. Review. Hungarian.

PMID:
19632916

Supplemental Content

Support Center